In Conversation With… Albert Whangbo, PhD
“Steroids are cheap and effective in the short term. Convincing payers that steroid-sparing therapies are worth the upfront cost is still a practical challenge.” Albert Whangbo, PhD, leads the global ...
Measuring What Matters: Steroid-toxicity and Patient Outcomes
Ten years ago, two clinical researchers walked into a bar and, over a beer, asked themselves whether the direct measurement of steroid-toxicity would ever be possible. Today, Steritas, in licensing ...
Would Steroids Be Approved for Clinical Use Today?
Despite their seemingly miraculous efficacy, the long-term adverse effects of glucocorticoids pose significant challenges. This reality led Ali A. Habib, MD and Pushpa Narayanaswami, MD to author an ...
In Conversation With… Glenn Philips, PhD
“We're using the same tools that demonstrate the benefit of our drugs to show that the long-term cost of steroids has been vastly underestimated.” Glenn Philips, PhD is the Vice President of Health ...
Quantifying the Risk-Benefit Ratio of Steroids in Myasthenia Gravis
A pioneering analysis of electronic health record (EHR) data from the Optum® EHR database has shown that it is finally possible to quantify the risk-to-benefit ratio of prescribing glucocorticoids, ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
